Blazing a New Path: An Innovative Approach to Screening Patients

Background

The pathophysiological process of Alzheimer’s Disease begins more than a decade before Alzheimer’s Disease dementia. In this stage, individuals have preserved cognitive abilities but underlying Alzheimer’s Disease pathophysiology, known as preclinical Alzheimer’s Disease. Consensus in the field is that compounds targeting the underlying disease process may have greater benefit when started earlier in the disease continuum, but no treatments that target the underlying pathology of Alzheimer’s Disease in this stage are currently available.